TNFRSF1A and colitis: Oral administration of the RIPK2 inhibitor BI 706039 in the tumor necrosis factor receptor 1 (TNFR1)-related unfolded protein response (UPR)-mediated colitis (TRUC) mouse model of spontaneous colitis significantly reduced histopathological inflammation scores in colonic tissues and related inflammatory markers, demonstrating the effectiveness of RIPK2 inhibitors in modulating intestinal immune system signaling [460].